These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29574039)

  • 41. Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396232
    [No Abstract]   [Full Text] [Related]  

  • 42. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
    Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.
    Waki K; Yokomizo K; Kawano K; Tsuda N; Komatsu N; Yamada A
    Cancer Immunol Immunother; 2020 Oct; 69(10):2001-2007. PubMed ID: 32393999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.
    Kobayashi Y; Sakura T; Miyawaki S; Toga K; Sogo S; Heike Y
    Cancer Immunol Immunother; 2017 Jul; 66(7):851-863. PubMed ID: 28321480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
    Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
    BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.
    Tiriveedhi V; Tucker N; Herndon J; Li L; Sturmoski M; Ellis M; Ma C; Naughton M; Lockhart AC; Gao F; Fleming T; Goedegebuure P; Mohanakumar T; Gillanders WE
    Clin Cancer Res; 2014 Dec; 20(23):5964-75. PubMed ID: 25451106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
    Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
    Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
    Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Litton JK; Shumway NM; Hale DF; Murray JL; Perez SA; Ponniah S; Baxevanis CN; Papamichail M; Peoples GE
    Oncotarget; 2016 Oct; 7(40):66192-66201. PubMed ID: 27589688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
    Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
    Adotévi O; Vernerey D; Jacoulet P; Meurisse A; Laheurte C; Almotlak H; Jacquin M; Kaulek V; Boullerot L; Malfroy M; Orillard E; Eberst G; Lagrange A; Favier L; Gainet-Brun M; Doucet L; Teixeira L; Ghrieb Z; Clairet AL; Guillaume Y; Kroemer M; Hocquet D; Moltenis M; Limat S; Quoix E; Mascaux C; Debieuvre D; Fagnoni-Legat C; Borg C; Westeel V
    J Clin Oncol; 2023 Jan; 41(2):373-384. PubMed ID: 36070539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
    Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
    Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses.
    Sawutdeechaikul P; Cia F; Bancroft G; Wanichwecharungruang S; Sittplangkoon C; Palaga T
    J Microbiol Biotechnol; 2019 Mar; 29(3):489-499. PubMed ID: 30691253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
    Disis ML; Schiffman K; Gooley TA; McNeel DG; Rinn K; Knutson KL
    Clin Cancer Res; 2000 Apr; 6(4):1347-50. PubMed ID: 10778962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination as a treatment for breast or ovarian cancer.
    Holmberg LA; Sandmaier B
    Expert Rev Vaccines; 2004 Jun; 3(3):269-77. PubMed ID: 15176943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
    Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
    J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Invariant chain-peptide fusion vaccine using HER-2/neu.
    Perez SA; Peoples GE; Papamichail M; Baxevanis CN
    Methods Mol Biol; 2014; 1139():321-36. PubMed ID: 24619690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
    J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.